Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
Authors
Keywords
Tocilizumab, COVID-19, COVID-19 pandemic, Coronavirus, Interleukin 6, Multicenter trial
Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 89, Issue -, Pages 107102
Publisher
Elsevier BV
Online
2020-10-13
DOI
10.1016/j.intimp.2020.107102
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pathological findings of COVID-19 associated with acute respiratory distress syndrome
- (2020) Zhe Xu et al. Lancet Respiratory Medicine
- Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
- (2020) Ruggero Capra et al. European Journal of Internal Medicine
- Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy
- (2020) Valentina Morena et al. European Journal of Internal Medicine
- Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
- (2020) Corrado Campochiaro et al. European Journal of Internal Medicine
- The SARS-CoV-2 outbreak: What we know
- (2020) Di Wu et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State
- (2020) Matt Arentz et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan
- (2020) Xiaochen Li et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Clinical and immunological features of severe and moderate coronavirus disease 2019
- (2020) Guang Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis
- (2020) Zhaohai Zheng et al. JOURNAL OF INFECTION
- Tocilizumab treatment in COVID-19: A single center experience
- (2020) Pan Luo et al. JOURNAL OF MEDICAL VIROLOGY
- Why tocilizumab could be an effective treatment for severe COVID-19?
- (2020) Binqing Fu et al. Journal of Translational Medicine
- Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China
- (2020) Yi Zheng et al. Journal of Zhejiang University-SCIENCE B
- Comorbidities and multi-organ injuries in the treatment of COVID-19
- (2020) Tianbing Wang et al. LANCET
- Effective treatment of severe COVID-19 patients with tocilizumab
- (2020) Xiaoling Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cytokine release syndrome in severe COVID-19
- (2020) John B. Moore et al. SCIENCE
- Immunomodulation in COVID-19
- (2020) Nicholas E Ingraham et al. Lancet Respiratory Medicine
- Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
- (2020) Jason Phua et al. Lancet Respiratory Medicine
- Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
- (2020) Yonggang Zhou et al. National Science Review
- Outcomes from intensive care in patients with COVID‐19: a systematic review and meta‐analysis of observational studies
- (2020) R. A. Armstrong et al. ANAESTHESIA
- Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China
- (2020) J. Zhang et al. CLINICAL MICROBIOLOGY AND INFECTION
- Tocilizumab for severe COVID-19: a systematic review and meta-analysis
- (2020) Shao-Huan Lan et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: A single‐center cohort study
- (2020) Mario Fernández‐Ruiz et al. JOURNAL OF MEDICAL VIROLOGY
- A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial
- (2020) Jonathan Rilinger et al. Trials
- Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy
- (2020) Giacomo Grasselli et al. JAMA Internal Medicine
- Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives
- (2020) Chandan Sarkar et al. Frontiers in Pharmacology
- Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials
- (2020) Alexandra Abrams-Downey et al. European Urology Focus
- Tocilizumab for the treatment of giant cell arteritis
- (2018) Michael Schirmer et al. Expert Review of Clinical Immunology
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
- (2018) Robert Q. Le et al. ONCOLOGIST
- Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
- (2014) Hermine I Brunner et al. ANNALS OF THE RHEUMATIC DISEASES
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
- (2013) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20
- (2013) Peter N. Morcos et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects
- (2013) Xiaoping Zhang et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
- (2013) Atsushi Ogata et al. ARTHRITIS CARE & RESEARCH
- Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis
- (2012) Shumpei Yokota et al. Therapeutic Advances in Musculoskeletal Disease
- IL-6: Regulator of Treg/Th17 balance
- (2010) Akihiro Kimura et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Tocilizumab for the treatment of rheumatoid arthritis
- (2010) Toshio Tanaka et al. Expert Review of Clinical Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation